NEW YORK (GenomeWeb) – Horizon Discovery today announced it has reached a non-exclusive licensing agreement with the Broad Institute for intellectual property related to the CRISPR-Cas9 gene editing system.

Horizon has gained the rights for the commercial use of the technology for applications such as the development of reagents and tools, as well as the provision of services that use CRISPR. Those services include Horizon's Genassist offering, which encompasses products and services for CRISPR and rAAV gene editing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.